Astec Chirobiotic: Macrocyclic Glycopeptide-Based Chiral HPLC Phases
Astec Chirobiotic: Macrocyclic Glycopeptide-Based Chiral HPLC Phases
*Astec CHIROBIOTIC V and T differ from V2 and T2, respectively, in their bonding Astec CHIROBIOTIC TAG – Teicoplanin Aglycone
chemistry that gives them different selectivity and preparative capacity for certain
classes of analytes.
C ionic
B
P-acceptor A
A, B, C are
inclusion sites
sugar
molecules
G004323
Polar Ionic Polar organic solvents Acids, Bases, Zwitterions (100:0.1:0.1, v:v:v) Change acid-base ratio,
(CH3OH or CH3CN) CH3OH:Acetic Acid: change the type of acid or
containing small amounts Triethylamine base, add a volatile salt (test
of acid and base or salt different ammonium salts)
Reversed-Phase Typical RP eluents, water Acids, Bases, Zwitterions, (30:70) CH3CN:20mM Change the % and type of
or buffers with CH3OH Neutrals Ammonium Acetate, pH 4.0 organic modifier, adjust pH,
or CH3CN buffer type, and ionic strength
Polar Organic Polar organic solvents Neutrals 100% Ethanol Use other polar organic
without ionic additives solvents or blends
Normal Phase Non-polar organic solvents Neutrals (30:70) Ethanol:Heptane Increase % of polar modifier,
with polar solvent modifiers change both solvents
Method Optimization: Acid-Base Ratio, Temperature, and Flow Rate in Polar Ionic Mode
Using Astec CHIROBIOTIC CSPs in the polar ionic mode has The acid, base, or salt that is ultimately selected is based on its
the highest probability of success. Optimizing resolution compatibility, with the detection method (e.g. LC-MS), sample
usually involves changing the contribution to retention of ionic solubility, and whether the separation will be scaled up to
interactions between the analytes and functional groups in the preparative.
macrocyclic glycopeptide structure by:
Changing the ratio of acid to base (Figure 2)
Adding a soluble, volatile salt (instead of the acid and base)
directly to the methanol
Acid:base ratio=1:1
7.36
G004324
G004327
100/0.15/0.05 10.44
Acid:base ratio=3:1
ionic interaction
interaction
24
Ketoprofen
CPS
* 12
G004332
0
0 5 10
Min G004331
Figure 4. ESI-MS of Clenbuterol Extracted from Plasma on Astec CHIROBIOTIC T in Polar Ionic Mode
column: Astec CHIROBIOTIC T, 10 cm x 2.1 mm, 5 μm particles (12018AST)
mobile phase: 10 mM ammonium formate in CH3OH
flow rate: 0.3 mL/min. 700
det.: ESI(+)
temp.: 30 °C 600
analyte: Clenbuterol in rat plasma (10 ng/mL)
500
300
*
Phospholipids
200
100
G004333
0
0 1 2 3 4 5
Min G004245
*
Clenbuterol
G004333
Metoprolol
Metoprolol
*
G004335
Sotalol Sotalol
Atenolol
*
G004334
Atenolol
*
0 12 24
G004336 Min G004337
4.65 G004348
5.22
0 4 8
Min G004349
1
Thalidomide Mephenytoin
G004346
G004344
0 7 14 0 10 20
Min G004347 Min G004345
7.13
7.17
7.57
4.53 G004339
TRADEMARKS:
Astec CHIROBIOTIC, CYCLOBOND, HybridSPE, P-CAP – Sigma-Aldrich Biotechnology LP
003338
Enabling Science to Order/Customer Service (800) 325-3010 :Fax (800) 325-5052 World Headquarters
Technical Service (800) 325-5832 :sigma-aldrich.com/techservice #%
$
Improve the Quality of Life $!%
"
Development/Custom Manufacturing Inquiries (800) 244-1173
Safety-related Information sigma-aldrich.com/safetycenter sigma-aldrich.com
1 #!&
%*#"(
%%*#!",+*+*.
'*,*&*$+%('!#'!,(#!&
%*#"('#,+2%#,#!&
%*#"
#(,"'(%(!0#!&*')*(-,+*+(%,"*(-!"#!&
%*#"'#!&
%*#"'/**',+,",#,+)*(-,+(' (*&,(,"#' (*&,#('(',#'#',"#+'(,"*#!&
%*#" KWY
)-%#,#('+-*"+*&-+,,*&#',"+-#,#%#,0( ,")*(-,+ (*,"#*)*,#-%*-+
#,#('%,*&+'('#,#('+&0))%0%++*.*++#( ,"#'.(#(*)$#'!+%#) T408131A